Dr. Robert S. Rosenson, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 245
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: Tulane University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
NY license 253461
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Sinai Hospital New York, NY
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 245
- Services billed
- 522
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 329 | 184 |
| Established patient office or other outpatient visit, 40-54 minutes | 98 | 72 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 93 | 78 |
| New patient office or other outpatient visit, 45-59 minutes | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Repatha Sureclick (evolocumab) Other prescribers in New York, NY | 352 |
| Ezetimibe Other prescribers in New York, NY | 314 |
| Rosuvastatin Calcium Other prescribers in New York, NY | 285 |
| Metoprolol Succinate Other prescribers in New York, NY | 139 |
| Praluent Pen (alirocumab) Other prescribers in New York, NY | 137 |
| Telmisartan Other prescribers in New York, NY | 132 |
| Amlodipine Besylate Other prescribers in New York, NY | 128 |
| Atorvastatin Calcium Other prescribers in New York, NY | 103 |
| Mounjaro (tirzepatide) Other prescribers in New York, NY | 100 |
| Olmesartan Medoxomil Other prescribers in New York, NY | 65 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 17 payments worth $10,717 in total to this clinician.
| AstraZeneca UK Limited | $7,812 |
|---|---|
| Eli Lilly and Company | $1,310 |
| Novo Nordisk Inc | $1,178 |
| AstraZeneca Pharmaceuticals LP | $125 |
| Amgen Inc. | $121 |
| Corcept Therapeutics | $84.34 |
| Novartis Pharmaceuticals Corporation | $48.83 |
| AstraZeneca Ab | $20.77 |
| Consulting Fee | $9,978 |
|---|---|
| Food and Beverage | $739 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca UK Limited Sep 23, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,000 |
| AstraZeneca UK Limited Dec 12, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $2,000 |
| AstraZeneca UK Limited Sep 19, 2025 | Consulting Fee | $1,600 |
| Eli Lilly and Company Jan 13, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,200 |
| Novo Nordisk Inc Nov 11, 2025 | Consulting Fee Cardiovascular | $1,178 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 4 companies. The companies reported $1,156,277 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Amgen Inc. - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiogra…
Novartis Pharmaceuticals Corporation - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc. - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - An Open-label, Single Arm, Multicenter Extension Study to Evaluate Long-term Safety and Tolerability of Inclisiran in Participants With Heterozygous or Homozygous Familial Hypercholesterolemia Who Have Completed the A…
Novartis Pharmaceuticals Corporation - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals Corporation - The Effects of Evolocumab on Endothelial and Inflammatory Biocellular Markers in Patients with Diabetes and Atherosclerotic Vascular Disease (METCHNIKOFF)
Amgen Inc. - KJX839B12302
Novartis Pharma AG
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.